Agreements reached under this partnership
Business alliance- 1
Products covered: Human (allogeneic) bone marrow-derived somatic stem cell culture supernatant (HLSI071)
- 2
For ongoing orders, the Company and JENECELL have agreed on shipment volumes, shipment timing and other details.
These are items that the documents state the two companies will work on. The lines above and below represent arrangements between the two companies.
The Company expects to receive payment for sales from JENECELL from the third quarter of the fiscal year ending December 2026 onward, and will recognize revenue each time products are delivered to JENECELL. The Company plans to disclose the sales amount for the initial order once the sale has been finalized.
| Item | Details |
|---|---|
| Name of alliance partner | 株式会社JENECELL |
| Alliance partner's business activities | Manufacture, wholesale and retail of pharmaceuticals, cosmetics, cosmetic ingredients and medical devices, among other products and services |
| Alliance partner's location | South Korea（Seoul） |
| Alliance partner's capital | 3,000,000,000 won (as of the end of March 2026) |
| Type of alliance | Business alliance |
| Details of the alliance | Products covered: Human (allogeneic) bone marrow-derived somatic stem cell culture supernatant (HLSI071), For ongoing orders, the Company and JENECELL have agreed on shipment volumes, shipment timing and other details. |
| Date of board resolution | 7 April 2026 |
| Contract Date | 7 April 2026 |
| Alliance start date | From July 2026 onward (予定) |
| Impact on Business Performance | The Company expects to receive payment for sales from JENECELL from the third quarter of the fiscal year ending December 2026 onward, and will recognize revenue each time products are delivered to JENECELL. The Company plans to disclose the sales amount for the initial order once the sale has been finalized. |
Items this document does not state (13)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The Company is promoting the research and development, manufacture and sale of products based on somatic stem cell culture supernatant fluid, and entered into this agreement as part of those efforts. JENECELL will use the cell culture supernatant as a raw material for cosmetics supplied in South Korea and worldwide.